Abstract:OBJECTIVE This phase II clinical trial was designed to evaluate the efficacy and toxicity of recombinant human interleukin-11 (rhIL-11) derivative manufactured in China in the prevention and treatment of chemotherapy-induced thrombocytopenia in cancer patients. METHODS A total of 100 cancer patients with chemotherapy-induced thrombocytopenia (< or = 75 x 10(9)/L) were studied by self-cross control. Ninty-one of them received 2 cycles of chemotherapy. In the first cycle (control cycle) the patients received chemotherapy only, while in the second cycle (treatment cycle), the patients were given subcutaneous injection of rhIL-11 derivative (40 microg.kg(-1).d(-1)) once daily after chemotherapy for 10 consecutive days or more until platelet count reached > or = 300 x 10(9)/L. RESULTS 1. The patients with platelet count of < or = 75 x 10(9)/L was 89/89 in the control cycle and 44/89 in the treatment cycle (P = 0.00). The recovery time to the normal platelet count was 1-47 days (median 9 days) in the control cycle, and 1-18 days (median 5.5 days) in treatment cycle (P = 0.00). 2. Patients with platelet count of < or = 50 x 10(9)/L was 56/89 in the control cycle and 20/89 in the treatment cycle (P = 0.00). The recovery time to normal platelet count was 1-31 days (median 9 days) in the control cycle and 3-13 days (median 6 days) in the treatment cycle (P = 0.05). 3. The median nadir platelet count was 44 x 10(9)/L (range: 10 x 10(9)/L-75 x 10(9)/L) in the control cycle, and 83 x 10(9)/L (range: 10 x 10(9)/L-310 x 10(9)/L) in the treatment cycle (P = 0.00). The time of recovery to the normal platelet count was 1-31 days (median 6 days) in the control cycle, and 0-13 days (median 2 days) in the treatment cycle (P = 0.00). 4. Nine of 89 evaluable patients required platelet transfusion in the control cycle versus 1 of 89 patients in treatment cycle (P = 0.01), and the total platelet transfusion was 10 times in the control cycle versus once in the treatment cycle (P = 0.01). 5. The major adverse events associated with rhIL-11 derivative were: headache, fatigue, myalgia/arthralgia, edema and palpitation, etc. CONCLUSION rhIL-11 derivative can be safely and effectively used for the prevention and treatment for chemotherapy-induced thrombocytopenia.

Clinical Analysis of Recombinant Human Interleukin-11 in Treatment of Chemotherapy-Induced Thrombocytopenia in Patients with Malignant Tumors

Clinical Study of Interleukin-11(Il-11)in the Treatment of Thrombocytopenia Caused by the Chemotherapy of Malignant Tumor

Efficacy and safety of recombinant human interleukin-11 for the treatment of thrombocytopenia after chemotherapy: a Meta-analysis

Recombinant human interleukin-11 for treatment of chemotherapy-induced thrombocytopenia in patients with gastrointestinal cancer

Efficacy and safety of recombinant human interleukin-11 derivative in the prevention and treatment of chemotherapyinduced thrombocytopenia(20 cases)

Efficacy And Safety Of Recombinant Human Interlerukin-11 In The Treatment Of Chemotherapy-Induced Thrombocytopenia In Acute Lymphoblastic Leukemia

[The efficacy and mechanism of rhIL-11 in the management of chemotherapy-induced thrombocytopenia in acute leukemia].

[Phase II Clinical Trial on China Manufactured Recombinant Human Interleukin-11 Derivative in the Prevention and Treatment of Chemotherapy-Induced Thrombocytopenia].

[Clinical Study of Rhil-11 for Prevention and Treatment of Chemotherapy-Induced Thrombocytopenia].

Effect of recombinant human interleukin 11 on thrombocytopenia induced by chemotherapy in patient with acute lymphoblastic leukemia

Clinical Observation of Recombinant Human Interleukin 11 Derivative in the Treatment of Malignant Tumor Chemotherapy-induced Thrombocytopenia

Clinical study on rhIL- 11 ( juheli)'s therapeutic effects of treating thrombocytopenia induced by chemotheraphy in malignant tumor patients

The role of interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with solid tumors, lymphoma, acute myeloid leukemia and bone marrow failure syndromes

Effects of Recombinant Human Interleukin-11 on Animal Chemotherapeutic Thrombocytopenia

Meta Analysis of Recombinant Human Thrombopoietin in Chemotherapy Induced Thrombocytopenia

Elevated BNP caused by recombinant human interleukin-11 treatment in patients with chemotherapy-induced thrombocytopenia

Clinical Observation of Recombinant Human Interleukin-11 in Chronic Refractory Idiopathic Thrombocytopenic Purpura

Clinical Study of Juheli in Treatment and Prevention of Chemotherapy-Induced Thrombocytopenia

Clinical observation of recombinant human thrombopoietin and interleukin-11 for thrombocytopenia in patients with non-small cell lung cancer after chemotherapy

[Value of Recombinant Human Thrombopoietin in the Treatment of Chemotherapy-Induced Thrombocytopenia in Patients with Solid Tumor].

Efficacy of recombinant human interleukin-11 in preventing and treating oral mucositis after chemotherapy for patients with acute leukemia